Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Department of Pharmacy and Biotechnology, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
Curr Opin Virol. 2017 Dec;27:8-14. doi: 10.1016/j.coviro.2017.10.003. Epub 2017 Nov 6.
Parvovirus B19 (B19V) is a human pathogenic virus associated with a wide range of clinical conditions. In pregnancy, B19V poses a potential hazard to the fetus as crossing the placental barrier and infecting erythroid progenitor cells in bone marrow and liver, it blocks fetal erythropoiesis leading to profound anemia, hydrops and/or fetal death. The virus is not regarded as a teratogen, however more scientific awareness is emerging on mechanisms and consequences of intrauterine infection and possible sequelae in the neonatal development. Reliable diagnostic procedures and fetal management strategies, including intrauterine transfusion, are established. In spite of being a recognized fetotropic agent possibly leading to fetal loss, testing for B19V is not routinely included in preconception or antenatal screenings, possibly delaying the management of B19V-complicated pregnancies. Continuous advances in B19V research will provide for better diagnostic methods and algorithms, as well as for the development of effective prophylactic interventions and novel therapeutic options.
细小病毒 B19（B19V）是一种与多种临床情况相关的人类致病病毒。在妊娠期间，B19V 穿过胎盘屏障并感染骨髓和肝脏中的红系祖细胞，从而阻止胎儿的红细胞生成，导致严重贫血、水肿和/或胎儿死亡，对胎儿构成潜在危险。该病毒不被视为致畸剂，但是人们对宫内感染的机制和后果以及新生儿发育中可能出现的后遗症有了更多的科学认识。已经建立了可靠的诊断程序和胎儿管理策略，包括宫内输血。尽管细小病毒 B19 被认为是一种可能导致胎儿丢失的亲胎因子，但在孕前或产前筛查中并未常规检测 B19V，这可能会延误对细小病毒 B19 感染妊娠的处理。细小病毒 B19 研究的不断进展将提供更好的诊断方法和算法，以及开发有效的预防干预措施和新的治疗选择。
